Difference between revisions of "Main Page"
Warner-admin (talk | contribs) |
Warner-admin (talk | contribs) |
||
(41 intermediate revisions by the same user not shown) | |||
Line 6: | Line 6: | ||
</div> | </div> | ||
− | <div style="text-align:center"><big>HemOnc.org is the largest freely available medical wiki of [[:Category:Intervention_index|interventions]], [[:Category:Regimen_index|regimens]], and [[:Category:General_reference_pages|general information]] relevant to the fields of hematology and oncology | + | <div style="text-align:center"><big>HemOnc.org is the largest freely available medical wiki of [[:Category:Intervention_index|interventions]], [[:Category:Regimen_index|regimens]], and [[:Category:General_reference_pages|general information]] relevant to the fields of hematology and oncology. Any healthcare professional can [[How to contribute|sign up to contribute]]; the [[Eligibility criteria|accuracy and completeness of content]] is overseen by the [[Editorial Board]]. Heavily visited pages can be accessed directly from the menu on the left. If this is your first time visiting, please start with the '''[[Tutorial|the tutorial page]]''', review our '''[[philosophy]]''', or just start exploring!</big></div> |
{| class="wikitable" style="text-align:center; margin-left: auto; margin-right: auto; font-size:125%; font-weight: bold; width: 100%;" | {| class="wikitable" style="text-align:center; margin-left: auto; margin-right: auto; font-size:125%; font-weight: bold; width: 100%;" | ||
|- | |- | ||
− | !style="width: 25%; font-size:150%; background-color:#bdbdbd"|[[Tutorial#Regimens|<span style="color:black;">Regimens</span>]]: | + | !style="width: 25%; font-size:150%; background-color:#bdbdbd"|[[Tutorial#Regimens|<span style="color:black;">Regimens</span>]]: 5,087 |
− | !style="width: 25%; font-size:150%; background-color:#bdbdbd" | + | !style="width: 25%; font-size:150%; background-color:#bdbdbd"|<span style="color:#3c0008;">Guidelines: 1,217</span> |
− | !style="width: 25%; font-size:150%; background-color:#bdbdbd"|<span style="color:black;">Studies</span>: 6, | + | !style="width: 25%; font-size:150%; background-color:#bdbdbd"|<span style="color:black;">Studies</span>: 6,665 |
− | !style="width: 25%; font-size:150%; background-color:#bdbdbd"|<span style="color:black;">References</span>: 7, | + | !style="width: 25%; font-size:150%; background-color:#bdbdbd"|<span style="color:black;">References</span>: 7,589 |
|- | |- | ||
|} | |} | ||
Line 21: | Line 21: | ||
|style="width: 20%; font-size:125%; background-color:#de2d26"|[[#malignantheme|<span style="color:white;">Malignant Hematology</span>]] | |style="width: 20%; font-size:125%; background-color:#de2d26"|[[#malignantheme|<span style="color:white;">Malignant Hematology</span>]] | ||
|style="width: 20%; font-size:125%; background-color:#ba871a"|[[#peds|<span style="color:white;">Pediatrics</span>]] | |style="width: 20%; font-size:125%; background-color:#ba871a"|[[#peds|<span style="color:white;">Pediatrics</span>]] | ||
− | |style="width: 20%; font-size:125%; background-color:#4a1486"|[[#transplant|<span style="color:white;">Transplant</span>]] | + | |style="width: 20%; font-size:125%; background-color:#4a1486"|[[#transplant|<span style="color:white;">Transplant & IEC</span>]] |
|style="width: 20%; font-size:125%; background-color:#31a354"|[[#classicalheme|<span style="color:white;">Classical Hematology</span>]] | |style="width: 20%; font-size:125%; background-color:#31a354"|[[#classicalheme|<span style="color:white;">Classical Hematology</span>]] | ||
|- | |- | ||
Line 59: | Line 59: | ||
|style="background-color:#deebf7"|[[Adrenocortical carcinoma]] | |style="background-color:#deebf7"|[[Adrenocortical carcinoma]] | ||
|style="background-color:#deebf7"|[[Neuroendocrine tumor|Neuroendocrine tumor (NET)]] | |style="background-color:#deebf7"|[[Neuroendocrine tumor|Neuroendocrine tumor (NET)]] | ||
+ | |style="background-color:#deebf7"|[[Neuroendocrine carcinoma|Neuroendocrine carcinoma (NEC)]] | ||
|style="background-color:#deebf7"|[[Pancreatic NET]] | |style="background-color:#deebf7"|[[Pancreatic NET]] | ||
+ | |- | ||
|style="background-color:#deebf7"|[[Pheochromocytoma]] | |style="background-color:#deebf7"|[[Pheochromocytoma]] | ||
− | |||
|style="background-color:#deebf7"|[[Thyroid cancer]] | |style="background-color:#deebf7"|[[Thyroid cancer]] | ||
|style="background-color:#deebf7"|[[Thyroid cancer, differentiated|Differentiated thyroid cancer (DTC)]] | |style="background-color:#deebf7"|[[Thyroid cancer, differentiated|Differentiated thyroid cancer (DTC)]] | ||
|style="background-color:#deebf7"|[[Thyroid cancer, medullary|Medullary thyroid cancer (MTC)]] | |style="background-color:#deebf7"|[[Thyroid cancer, medullary|Medullary thyroid cancer (MTC)]] | ||
+ | |- | ||
|style="background-color:#deebf7"|[[Thyroid_cancer,_BRAF-mutated|Thyroid cancer, BRAF-mutated]] | |style="background-color:#deebf7"|[[Thyroid_cancer,_BRAF-mutated|Thyroid cancer, BRAF-mutated]] | ||
− | |||
|style="background-color:#deebf7"|[[Thyroid_cancer,_RET-positive|Thyroid cancer, RET-positive]] | |style="background-color:#deebf7"|[[Thyroid_cancer,_RET-positive|Thyroid cancer, RET-positive]] | ||
− | |||
|style="background-color:#deebf7"| | |style="background-color:#deebf7"| | ||
|style="background-color:#deebf7"| | |style="background-color:#deebf7"| | ||
Line 92: | Line 92: | ||
|style="width: 25%; background-color:#deebf7"|[[Gastric cancer, HER2-positive]] | |style="width: 25%; background-color:#deebf7"|[[Gastric cancer, HER2-positive]] | ||
|style="width: 25%; background-color:#deebf7"|[[Rectal cancer]] | |style="width: 25%; background-color:#deebf7"|[[Rectal cancer]] | ||
− | |style="background-color:#deebf7"| | + | |style="width: 25%; background-color:#deebf7"|[[Small bowel adenocarcinoma]] |
|- | |- | ||
|colspan="4" style="font-size:125%; background-color:#6baed6"|'''Gastrointestinal Oncology, Extraintestinal''' | |colspan="4" style="font-size:125%; background-color:#6baed6"|'''Gastrointestinal Oncology, Extraintestinal''' | ||
Line 102: | Line 102: | ||
|- | |- | ||
|style="width: 25%; background-color:#deebf7"|[[Pancreatic cancer|Pancreatic adenocarcinoma]] | |style="width: 25%; background-color:#deebf7"|[[Pancreatic cancer|Pancreatic adenocarcinoma]] | ||
− | |style="width: 25%; background-color:#deebf7"|[[Pancreatic cancer, BRCA-mutated| | + | |style="width: 25%; background-color:#deebf7"|[[Pancreatic cancer, BRCA-mutated|Pancreatic adenocarcinoma, BRCA-mutated]] |
|style="width: 25%; background-color:#deebf7"|[[Pancreatic NET]] | |style="width: 25%; background-color:#deebf7"|[[Pancreatic NET]] | ||
|style="background-color:#deebf7"| | |style="background-color:#deebf7"| | ||
Line 108: | Line 108: | ||
|colspan="4" style="font-size:125%; background-color:#6baed6"|'''Genitourinary Oncology''' | |colspan="4" style="font-size:125%; background-color:#6baed6"|'''Genitourinary Oncology''' | ||
|- | |- | ||
− | |||
|style="background-color:#deebf7"|[[Penile cancer]] | |style="background-color:#deebf7"|[[Penile cancer]] | ||
|style="background-color:#deebf7"|[[Prostate cancer]] | |style="background-color:#deebf7"|[[Prostate cancer]] | ||
|style="background-color:#deebf7"|[[Prostate cancer, BRCA-mutated]] | |style="background-color:#deebf7"|[[Prostate cancer, BRCA-mutated]] | ||
+ | |style="background-color:#deebf7"|[[Testicular cancer]] | ||
|- | |- | ||
|style="background-color:#deebf7"|[[Renal cell carcinoma|Renal cell carcinoma (RCC)]] | |style="background-color:#deebf7"|[[Renal cell carcinoma|Renal cell carcinoma (RCC)]] | ||
Line 120: | Line 120: | ||
|style="background-color:#deebf7"|[[Sarcomatoid renal cell carcinoma|Sarcomatoid RCC]] | |style="background-color:#deebf7"|[[Sarcomatoid renal cell carcinoma|Sarcomatoid RCC]] | ||
|style="background-color:#deebf7"|[[Renal_cell_carcinoma,_VHL-associated|VHL-associated RCC]] | |style="background-color:#deebf7"|[[Renal_cell_carcinoma,_VHL-associated|VHL-associated RCC]] | ||
− | |style="background-color:#deebf7"|[[ | + | |style="background-color:#deebf7"| |
+ | |style="background-color:#deebf7"| | ||
+ | |- | ||
+ | |style="background-color:#deebf7"|[[Urothelial carcinoma]] | ||
+ | |style="background-color:#deebf7"|[[Bladder cancer]] | ||
|style="background-color:#deebf7"|[[Upper tract urothelial carcinoma|Upper tract urothelial carcinoma (UTUC)]] | |style="background-color:#deebf7"|[[Upper tract urothelial carcinoma|Upper tract urothelial carcinoma (UTUC)]] | ||
+ | |style="background-color:#deebf7"| | ||
|- | |- | ||
|colspan="4" style="font-size:125%; background-color:#6baed6"|'''Gynecologic Oncology''' | |colspan="4" style="font-size:125%; background-color:#6baed6"|'''Gynecologic Oncology''' | ||
Line 144: | Line 149: | ||
|colspan="4" style="font-size:125%; background-color:#6baed6"|'''Mesothelioma''' | |colspan="4" style="font-size:125%; background-color:#6baed6"|'''Mesothelioma''' | ||
|- | |- | ||
− | |style="background-color:#deebf7"|[[Malignant peritoneal mesothelioma|Malignant peritoneal mesothelioma (MPEM)]] | + | |colspan="2" style="background-color:#deebf7"|[[Malignant peritoneal mesothelioma|Malignant peritoneal mesothelioma (MPEM)]] |
− | |style="background-color:#deebf7"|[[Malignant pleural mesothelioma|Malignant pleural mesothelioma (MPM)]] | + | |colspan="2" style="background-color:#deebf7"|[[Malignant pleural mesothelioma|Malignant pleural mesothelioma (MPM)]] |
− | |||
− | |||
|- | |- | ||
|colspan="4" style="font-size:125%; background-color:#6baed6"|'''Neuro-Oncology''' | |colspan="4" style="font-size:125%; background-color:#6baed6"|'''Neuro-Oncology''' | ||
|- | |- | ||
|style="background-color:#deebf7"|[[Anaplastic glioma]] | |style="background-color:#deebf7"|[[Anaplastic glioma]] | ||
+ | |style="background-color:#deebf7"|[[Craniopharyngioma]] | ||
|style="background-color:#deebf7"|[[Glioblastoma|Glioblastoma (GBM)]] | |style="background-color:#deebf7"|[[Glioblastoma|Glioblastoma (GBM)]] | ||
|style="background-color:#deebf7"|[[Low-grade glioma]] | |style="background-color:#deebf7"|[[Low-grade glioma]] | ||
+ | |- | ||
|style="background-color:#deebf7"|[[Meningioma]] | |style="background-color:#deebf7"|[[Meningioma]] | ||
− | |||
|style="background-color:#deebf7"|[[Subependymal giant cell astrocytoma|Subependymal giant cell astrocytoma (SEGA)]] | |style="background-color:#deebf7"|[[Subependymal giant cell astrocytoma|Subependymal giant cell astrocytoma (SEGA)]] | ||
− | |||
|style="background-color:#deebf7"| | |style="background-color:#deebf7"| | ||
|style="background-color:#deebf7"| | |style="background-color:#deebf7"| | ||
Line 169: | Line 172: | ||
|- | |- | ||
|style="background-color:#deebf7"|[[Bone sarcoma]] | |style="background-color:#deebf7"|[[Bone sarcoma]] | ||
+ | |style="background-color:#deebf7"|[[Ewing sarcoma]] | ||
+ | |style="background-color:#deebf7"|[[Giant-cell tumor of bone]] | ||
+ | |style="background-color:#deebf7"|[[Osteosarcoma]] | ||
+ | |- | ||
+ | |style="background-color:#deebf7"|[[Soft tissue sarcoma|Soft tissue sarcoma (STS)]] | ||
+ | |style="background-color:#deebf7"|[[Alveolar soft part sarcoma|Alveolar soft part sarcoma (ASPS)]] | ||
+ | |style="background-color:#deebf7"|[[Dermatofibrosarcoma protuberans]] | ||
|style="background-color:#deebf7"|[[Desmoid tumor]] | |style="background-color:#deebf7"|[[Desmoid tumor]] | ||
+ | |- | ||
|style="background-color:#deebf7"|[[Epithelioid sarcoma]] | |style="background-color:#deebf7"|[[Epithelioid sarcoma]] | ||
− | |style="background-color:#deebf7"|[[ | + | |style="background-color:#deebf7"|[[Gastrointestinal stromal tumor|Gastrointestinal stromal tumor (GIST)]] |
+ | |style="background-color:#deebf7"|[[Inflammatory myofibroblastic tumor|Inflammatory myofibroblastic tumor (IMT)]] | ||
+ | |style="background-color:#deebf7"|[[Leiomyosarcoma|Leiomyosarcoma (LMS)]] | ||
|- | |- | ||
− | |||
− | |||
|style="background-color:#deebf7"|[[Liposarcoma]] | |style="background-color:#deebf7"|[[Liposarcoma]] | ||
− | |||
− | |||
− | |||
|style="background-color:#deebf7"|[[PEComa]] | |style="background-color:#deebf7"|[[PEComa]] | ||
|style="background-color:#deebf7"|[[Rhabdomyosarcoma|Rhabdomyosarcoma (RMS)]] | |style="background-color:#deebf7"|[[Rhabdomyosarcoma|Rhabdomyosarcoma (RMS)]] | ||
− | |style="background-color:#deebf7"|[[ | + | |style="background-color:#deebf7"|[[Tenosynovial giant cell tumor|Tenosynovial giant cell tumor (TGCT)]] |
|- | |- | ||
− | |||
|style="background-color:#deebf7"|[[Vascular sarcoma]] | |style="background-color:#deebf7"|[[Vascular sarcoma]] | ||
− | |style="background-color:#deebf7"| | + | |style="background-color:#deebf7"|[[Angiosarcoma]] |
+ | |style="background-color:#deebf7"|[[Kaposi sarcoma|Kaposi sarcoma (KS)]] | ||
|style="background-color:#deebf7"| | |style="background-color:#deebf7"| | ||
|- | |- | ||
Line 219: | Line 227: | ||
|style="background-color:#deebf7"|[[MSI-H or dMMR]] | |style="background-color:#deebf7"|[[MSI-H or dMMR]] | ||
|style="background-color:#deebf7"|[[NTRK]] | |style="background-color:#deebf7"|[[NTRK]] | ||
+ | |style="background-color:#deebf7"|[[RET]] | ||
|style="background-color:#deebf7"|[[SMO or PTCH-1 (Hedgehog)]] | |style="background-color:#deebf7"|[[SMO or PTCH-1 (Hedgehog)]] | ||
+ | |- | ||
|style="background-color:#deebf7"|[[TMB-H]] | |style="background-color:#deebf7"|[[TMB-H]] | ||
− | |||
|style="background-color:#deebf7"|[[Carcinoma of unknown primary|Carcinoma of unknown primary (CUP)]] | |style="background-color:#deebf7"|[[Carcinoma of unknown primary|Carcinoma of unknown primary (CUP)]] | ||
− | |||
|style="background-color:#deebf7"| | |style="background-color:#deebf7"| | ||
|style="background-color:#deebf7"| | |style="background-color:#deebf7"| | ||
Line 266: | Line 274: | ||
|- | |- | ||
|style="background-color:#fee0d2"|[[Burkitt lymphoma|Burkitt lymphoma (BL) or Burkitt-like lymphoma]] | |style="background-color:#fee0d2"|[[Burkitt lymphoma|Burkitt lymphoma (BL) or Burkitt-like lymphoma]] | ||
+ | |style="background-color:#fee0d2"|[[Classical Hodgkin lymphoma|Classical Hodgkin lymphoma (cHL)]] | ||
|style="background-color:#fee0d2"|[[CNS lymphoma]] | |style="background-color:#fee0d2"|[[CNS lymphoma]] | ||
|style="background-color:#fee0d2"|[[Diffuse large B-cell lymphoma|Diffuse large B-cell lymphoma (DLBCL)]] | |style="background-color:#fee0d2"|[[Diffuse large B-cell lymphoma|Diffuse large B-cell lymphoma (DLBCL)]] | ||
+ | |- | ||
+ | |style="background-color:#fee0d2"|[[High-grade B-cell lymphoma]] | ||
|style="background-color:#fee0d2"|[[HIV-associated lymphoma]] | |style="background-color:#fee0d2"|[[HIV-associated lymphoma]] | ||
− | |||
− | |||
|style="background-color:#fee0d2"|[[Mantle cell lymphoma|Mantle cell lymphoma (MCL)]] | |style="background-color:#fee0d2"|[[Mantle cell lymphoma|Mantle cell lymphoma (MCL)]] | ||
|style="background-color:#fee0d2"|[[Mediastinal gray-zone lymphoma|Mediastinal gray-zone lymphoma (MGZL)]] | |style="background-color:#fee0d2"|[[Mediastinal gray-zone lymphoma|Mediastinal gray-zone lymphoma (MGZL)]] | ||
+ | |- | ||
|style="background-color:#fee0d2"|[[Primary mediastinal B-cell lymphoma|Primary mediastinal B-cell lymphoma (PMBL)]] | |style="background-color:#fee0d2"|[[Primary mediastinal B-cell lymphoma|Primary mediastinal B-cell lymphoma (PMBL)]] | ||
− | |||
|style="background-color:#fee0d2"|[[Transformed lymphoma|Transformed lymphoma (TL)]] | |style="background-color:#fee0d2"|[[Transformed lymphoma|Transformed lymphoma (TL)]] | ||
− | |||
|style="background-color:#fee0d2"| | |style="background-color:#fee0d2"| | ||
|style="background-color:#fee0d2"| | |style="background-color:#fee0d2"| | ||
Line 326: | Line 334: | ||
|colspan="2" style="background-color:#fee0d2"|[[Post-transplant lymphoproliferative disorder|Post-transplant lymphoproliferative disorder (PTLD)]] | |colspan="2" style="background-color:#fee0d2"|[[Post-transplant lymphoproliferative disorder|Post-transplant lymphoproliferative disorder (PTLD)]] | ||
|- | |- | ||
− | |colspan="4" style="font-size:125%; background-color:#fc9272"|''' | + | |colspan="4" style="font-size:125%; background-color:#fc9272"|'''Histiocytic disorders''' |
|- | |- | ||
|style="background-color:#fee0d2"|[[Erdheim-Chester disease|Erdheim-Chester disease (ECD)]] | |style="background-color:#fee0d2"|[[Erdheim-Chester disease|Erdheim-Chester disease (ECD)]] | ||
Line 358: | Line 366: | ||
|style="background-color:#e8d7b3"| | |style="background-color:#e8d7b3"| | ||
|- | |- | ||
− | |style="background-color:#e8d7b3"|[[Hodgkin lymphoma, pediatric | Hodgkin lymphoma ( | + | |style="background-color:#e8d7b3"|[[Classical Hodgkin lymphoma, pediatric |Classical Hodgkin lymphoma (cHL)]] |
|style="background-color:#e8d7b3"|[[Non-Hodgkin lymphoma, pediatric | Non-Hodgkin lymphoma (NHL)]] | |style="background-color:#e8d7b3"|[[Non-Hodgkin lymphoma, pediatric | Non-Hodgkin lymphoma (NHL)]] | ||
|style="background-color:#e8d7b3"| | |style="background-color:#e8d7b3"| | ||
Line 379: | Line 387: | ||
{| class="wikitable" style="text-align:center; margin-left: auto; margin-right: auto; font-weight: bold; width: 100%;" | {| class="wikitable" style="text-align:center; margin-left: auto; margin-right: auto; font-weight: bold; width: 100%;" | ||
− | !colspan="4" align="center" style="color:white; font-size:150%; background-color:#4a1486"|'''Transplant''' | + | !colspan="4" align="center" style="color:white; font-size:150%; background-color:#4a1486"|'''Transplant and Immune Effector Cells (IECs)''' |
|- | |- | ||
|style="width: 25%; background-color:#efedf5"|[[Stem cell mobilization]] | |style="width: 25%; background-color:#efedf5"|[[Stem cell mobilization]] | ||
|style="width: 25%; background-color:#efedf5"|[[Allogeneic HSCT]] | |style="width: 25%; background-color:#efedf5"|[[Allogeneic HSCT]] | ||
|style="width: 25%; background-color:#efedf5"|[[Autologous HSCT]] | |style="width: 25%; background-color:#efedf5"|[[Autologous HSCT]] | ||
− | |style="width: 25%; background-color:#efedf5"|[[Graft versus host disease|Graft versus host disease (GVHD)]] | + | |style="width: 25%; background-color:#efedf5"|[[Chimeric antigen receptor T cells (CAR-T)]] |
+ | |- | ||
+ | |style="background-color:#efedf5"|[[Graft versus host disease|Graft versus host disease (GVHD)]] | ||
+ | |style="background-color:#efedf5"|[[Hepatic veno-occlusive disease|Hepatic veno-occlusive disease (VOD/SOS)]] | ||
+ | |style="background-color:#efedf5"| | ||
+ | |style="background-color:#efedf5"| | ||
|- | |- | ||
|} | |} | ||
Line 395: | Line 408: | ||
|- | |- | ||
|style="width: 25%; background-color:#e5f5e0"|[[Acquired coagulopathy]] | |style="width: 25%; background-color:#e5f5e0"|[[Acquired coagulopathy]] | ||
+ | |style="width: 25%; background-color:#e5f5e0"|[[Acquired thrombotic thrombocytopenic purpura|Acquired thrombotic thrombocytopenic purpura (aTTP)]] | ||
|style="width: 25%; background-color:#e5f5e0"|[[Antiphospholipid antibody syndrome|Antiphospholipid antibody syndrome (APLAS)]] | |style="width: 25%; background-color:#e5f5e0"|[[Antiphospholipid antibody syndrome|Antiphospholipid antibody syndrome (APLAS)]] | ||
+ | |style="width: 25%; background-color:#e5f5e0"|[[Congenital thrombotic thrombocytopenic purpura|Congenital thrombotic thrombocytopenic purpura (cTTP)]] | ||
+ | |- | ||
|style="width: 25%; background-color:#e5f5e0"|[[Heparin-induced thrombocytopenia|Heparin-induced thrombocytopenia (HIT)]] | |style="width: 25%; background-color:#e5f5e0"|[[Heparin-induced thrombocytopenia|Heparin-induced thrombocytopenia (HIT)]] | ||
|style="width: 25%; background-color:#e5f5e0"|[[Hereditary hemorrhagic telangiectasia|Hereditary hemorrhagic telangiectasia (HHT)]] | |style="width: 25%; background-color:#e5f5e0"|[[Hereditary hemorrhagic telangiectasia|Hereditary hemorrhagic telangiectasia (HHT)]] | ||
− | |||
|style="width: 25%; background-color:#e5f5e0"|[[Inherited coagulopathy]] | |style="width: 25%; background-color:#e5f5e0"|[[Inherited coagulopathy]] | ||
|style="background-color:#e5f5e0"|[[Inherited thrombophilia]] | |style="background-color:#e5f5e0"|[[Inherited thrombophilia]] | ||
+ | |- | ||
+ | |style="background-color:#e5f5e0"|[[Thrombotic microangiopathy|Thrombotic microangiopathy (TMA)]] | ||
|style="background-color:#e5f5e0"|[[Venous thromboembolism|Venous thromboembolism (VTE)]] | |style="background-color:#e5f5e0"|[[Venous thromboembolism|Venous thromboembolism (VTE)]] | ||
+ | |style="background-color:#e5f5e0"| | ||
|style="background-color:#e5f5e0"| | |style="background-color:#e5f5e0"| | ||
|- | |- | ||
Line 416: | Line 434: | ||
|style="background-color:#e5f5e0"| | |style="background-color:#e5f5e0"| | ||
|- | |- | ||
− | |colspan="4" style="font-size:125%; background-color:#a1d99b"|'''Hemolytic disorders''' | + | |colspan="4" style="font-size:125%; background-color:#a1d99b"|'''Hemolytic disorders and Hemoglobinopathies''' |
|- | |- | ||
|style="background-color:#e5f5e0"|[[Atypical hemolytic uremic syndrome|Atypical hemolytic uremic syndrome (aHUS)]] | |style="background-color:#e5f5e0"|[[Atypical hemolytic uremic syndrome|Atypical hemolytic uremic syndrome (aHUS)]] | ||
Line 423: | Line 441: | ||
|style="background-color:#e5f5e0"|[[Paroxysmal nocturnal hemoglobinuria|Paroxysmal nocturnal hemoglobinuria (PNH)]] | |style="background-color:#e5f5e0"|[[Paroxysmal nocturnal hemoglobinuria|Paroxysmal nocturnal hemoglobinuria (PNH)]] | ||
|- | |- | ||
− | |style="background-color:#e5f5e0"|[[ | + | |style="background-color:#e5f5e0"|[[Pyruvate kinase deficiency|Pyruvate kinase deficiency (PKD)]] |
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
|style="background-color:#e5f5e0"|[[Beta thalassemia]] | |style="background-color:#e5f5e0"|[[Beta thalassemia]] | ||
|style="background-color:#e5f5e0"|[[Sickle cell anemia]] | |style="background-color:#e5f5e0"|[[Sickle cell anemia]] | ||
− | |||
|style="background-color:#e5f5e0"| | |style="background-color:#e5f5e0"| | ||
|- | |- | ||
Line 445: | Line 456: | ||
Priorities of this project include: | Priorities of this project include: | ||
+ | <section begin=goals /> | ||
*'''Creating a database of all [[Drug index | approved systemic anticancer therapy agents and supportive medications used in the field of hematology/oncology]]. | *'''Creating a database of all [[Drug index | approved systemic anticancer therapy agents and supportive medications used in the field of hematology/oncology]]. | ||
*'''Creating a database of all standard-of-care systemic anticancer therapy regimens and references to primary literature (PubMed and direct links to the abstracts articles). | *'''Creating a database of all standard-of-care systemic anticancer therapy regimens and references to primary literature (PubMed and direct links to the abstracts articles). | ||
Line 450: | Line 462: | ||
*'''Aggregating [[External links|useful links]] to existing resources by disease, such as guidelines, information about prognosis, clinical calculators, staging, and patient resources. | *'''Aggregating [[External links|useful links]] to existing resources by disease, such as guidelines, information about prognosis, clinical calculators, staging, and patient resources. | ||
*'''Creating, maintaining, and disseminating a [[Ontology|formalized ontology]] of anticancer drugs and regimens. | *'''Creating, maintaining, and disseminating a [[Ontology|formalized ontology]] of anticancer drugs and regimens. | ||
+ | <section end=goals /> | ||
Additional possibilities for this project may include: | Additional possibilities for this project may include: |
Revision as of 12:20, 1 June 2024
HemOnc.org - A Free Hematology/Oncology Reference
Regimens: 5,087 | Guidelines: 1,217 | Studies: 6,665 | References: 7,589 |
---|
Solid Tumors | Malignant Hematology | Pediatrics | Transplant & IEC | Classical Hematology |
Links to all main disease pages
Pediatric Neoplasms | |||
---|---|---|---|
Pediatric CNS malignancies | |||
Low-grade glioma | High-grade glioma | Medulloblastoma | |
Pediatric hematologic neoplasms | |||
B-cell acute lymphoblastic leukemia (B-ALL) | B-ALL, Ph+ | T-cell acute lymphoblastic leukemia (T-ALL) | Acute myeloid leukemia (AML) |
Anaplastic large cell lymphoma (ALCL) | Chronic myeloid leukemia (CML) | Juvenile myelomonocytic leukemia (JMML) | |
Classical Hodgkin lymphoma (cHL) | Non-Hodgkin lymphoma (NHL) | ||
Pediatric solid tumors | |||
Epithelioid sarcoma | Ewing sarcoma | Hepatoblastoma | Neuroblastoma |
Osteosarcoma | Rhabdomyosarcoma | Wilms tumor |
Transplant and Immune Effector Cells (IECs) | |||
---|---|---|---|
Stem cell mobilization | Allogeneic HSCT | Autologous HSCT | Chimeric antigen receptor T cells (CAR-T) |
Graft versus host disease (GVHD) | Hepatic veno-occlusive disease (VOD/SOS) |
Additional Information
Created as a knowledge base for hematology & oncology providers, HemOnc.org is a collaborative wiki containing details about hundreds of hematology/oncology drugs, and thousands of treatment regimens. Content is added by hematology & oncology professionals, and undergoes continuous peer review.
Any information that one feels would be helpful to other oncology providers is welcome. Visit how to contribute for more details.
Priorities of this project include:
- Creating a database of all approved systemic anticancer therapy agents and supportive medications used in the field of hematology/oncology.
- Creating a database of all standard-of-care systemic anticancer therapy regimens and references to primary literature (PubMed and direct links to the abstracts articles).
- Sample order sets and examples of supportive medications used with treatment regimens
- Aggregating useful links to existing resources by disease, such as guidelines, information about prognosis, clinical calculators, staging, and patient resources.
- Creating, maintaining, and disseminating a formalized ontology of anticancer drugs and regimens.
Additional possibilities for this project may include:
- Creating synopses of pivotal clinical trials and regimens
- Prioritizing regimens by their efficacy and/or toxicity
- Capturing historical regimens that were standard-of-care prior to 2005
- Checklists for common clinical scenarios/diseases
- Creating checklists that can be used for patients starting therapy with particular regimens, such as laboratory & imaging (e.g. echocardiogram, PFTs) parameters to monitor and informed consent/discussion of side effects
The field of hematology/oncology is ever-changing, and our hope is that other people will be interested in contributing to make it an increasingly more useful resource. The rapidly evolving nature of the practice demands a more dynamic medium than existing resources can provide and would benefit from being able to be updated in real-time from virtually any computer with internet access. We believe that the familiar format of a Wiki, made popular by sites such as Wikipedia, will significantly help ease-of-use and navigation.